Dr. Michelle Dipp, M.D., Ph.D., joined General Atlantic in 2017 as Managing Director based in the firm’s New York Office. Dr. Dipp will be a senior member of the firm’s Global Healthcare team and will focus on biopharma and life sciences investments.
Prior to joining General Atlantic, Dr. Dipp served as Co-Founder and General Partner of Longwood Fund, a healthcare venture capital firm. In this role, she served as a General Partner in Longwood Funds I, II, III, and IV. Additionally, Dr. Dipp co-founded several Longwood Fund portfolio companies, where she held senior management and board positions, including co-founding Chairman of Axial Biotherapeutics as well as co-founding CEO, and later Chairman, of OvaScience, Inc. Dr. Dipp also served as a Co-Founder of Longwood Fund portfolio companies Alnara Pharmaceuticals, Inc., Flex Pharma, Inc., and Verastem, Inc., as well as a board member of Colorescience, and a board observer of Bicycle Therapeutics and Pulmocide Ltd.
Previously, Dr. Dipp was the Senior Vice President and Head of GlaxoSmithKline’s Centre of Excellence for External Drug Discovery, a global business development and mergers and acquisitions group. Dr. Dipp joined GSK through the acquisition of Sirtris, where she served as the Vice President of Corporate Development.
Dr. Dipp is a member of the World Economic Forum's Young Global Leaders and currently serves on the Board of Directors for Life Science Cares. She is also a women's health contributor for Arianna Huffington's Thrive Global. Dr. Dipp formerly served on the Biotechnology Industry Organization's (BIO) Emerging Companies Governing Board, the New England Venture Capital Association (NEVCA) Board of Directors, the Beth Israel Deaconess Medical Center Board of Directors, the Boston Symphony Orchestra Board of Overseers, and the City on a Hill Charter School Board of Directors.
She holds a Bachelor of Medicine and Bachelor of Surgery from the University of Oxford Medical School and a Doctor of Philosophy in Human Physiology from the University of Oxford.